Our findings indicated that both SOX2 and OCT3/4 could serve as biomarkers that could improve risk stratification of acute leukemia patients. Also, both SOX2 and OCT3/4 might be a therapeutic target, especially in resistant acute leukemia.
Keyphrases
- transcription factor
- optical coherence tomography
- stem cells
- end stage renal disease
- diabetic retinopathy
- newly diagnosed
- induced apoptosis
- ejection fraction
- poor prognosis
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- cell cycle arrest
- acute myeloid leukemia
- dendritic cells
- patient reported outcomes
- signaling pathway
- cell proliferation
- cell death
- binding protein
- immune response
- young adults
- childhood cancer